Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New allergy pill shows promise in ragweed season trial

NCT ID NCT06922448

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This study tested a new drug called BLU-808 in 21 adults with ragweed allergies. The goal was to see if it is safe and helps reduce sneezing, runny nose, and itchy eyes caused by ragweed pollen. Participants were exposed to ragweed in a special chamber to measure the drug's effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

21 people

The number who actually took part.

Started

Apr 2025

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria 1. Adults, 18 years of age or older, willing to provide written informed consent, and willing to comply with all study requirements. 2. History (\>2 years) of ragweed-induced ARC. 3. A positive ragweed skin prick test (mean diameter of ≥ 5 mm) in the last 6 months. 4. Must meet clinically relevant nasal and ocular symptoms as defined by the protocol. Key Exclusion Criteria Participants are excluded from the study if any of the following criteria are met: 1. Receiving medications (oral, nasal, topical, ocular, or injectable) to treat their ragweed or other allergy symptoms and/or receiving any medications that impact participants' safety or interfere with study assessments or interpretation of study results. 2. Have active rhinitis, sinusitis, and/or other severe allergies not associated with the ragweed pollen that may interfere with study symptom assessments. 3. Any prior or ongoing clinically significant illness, medical or psychiatric condition, surgical history, or physical finding that may interfere with the assessment or interpretation of study results. 4. Clinically significant moderate to severe, uncontrolled cardiovascular, renal or hepatic disease. 5. Significant bleeding risk or coagulation disorders. 6. Any form of smoking, vaping or history of alcohol and drug abuse. 7. Any malignancy within the past 5 years prior to Screening/AEC 1, except for basal cell or squamous cell carcinomas of the skin or carcinoma in situ. 8. Inadequately controlled asthma that could affect the safety of the participant or interfere with the assessment or interpretation of study results. 9. Known active/latent infection (viral, bacterial, fungal, helminth, or mycobacterial) such as tuberculosis, hepatitis B, hepatitis C, AIDS-related illness, or COVID-19 infection. 10. History of sinonasal conditions that may confound the assessment or interpretation of study results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergic rhinoconjunctivitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Red Maple Trials

    Ottawa, ON K1H E4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.